Repligen (NASDAQ:RGEN) Given Outperform Rating at Wolfe Research

Repligen (NASDAQ:RGEN)‘s stock had its “outperform” rating reiterated by research analysts at Wolfe Research in a note issued to investors on Tuesday,Benzinga reports. They presently have a $145.00 price target on the biotechnology company’s stock. Wolfe Research’s target price would suggest a potential upside of 17.79% from the company’s current price.

RGEN has been the subject of a number of other research reports. Weiss Ratings raised shares of Repligen from a “sell (d)” rating to a “sell (d+)” rating in a report on Thursday, May 7th. UBS Group reduced their price target on shares of Repligen from $200.00 to $195.00 and set a “buy” rating on the stock in a research report on Wednesday, February 25th. Rothschild & Co Redburn set a $160.00 price objective on shares of Repligen and gave the company a “buy” rating in a research report on Friday, April 17th. Jefferies Financial Group reaffirmed a “hold” rating and set a $142.00 price target on shares of Repligen in a research report on Tuesday, May 5th. Finally, Royal Bank Of Canada started coverage on shares of Repligen in a research note on Thursday, May 14th. They set an “outperform” rating and a $160.00 price objective for the company. Two investment analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Repligen currently has a consensus rating of “Moderate Buy” and an average target price of $164.64.

Repligen Trading Down 0.7%

Repligen stock opened at $123.10 on Tuesday. The company has a debt-to-equity ratio of 0.26, a current ratio of 9.20 and a quick ratio of 7.78. The company has a market capitalization of $6.94 billion, a price-to-earnings ratio of 136.78, a PEG ratio of 2.39 and a beta of 1.09. Repligen has a one year low of $100.99 and a one year high of $175.77. The company’s fifty day moving average price is $118.05 and its two-hundred day moving average price is $139.53.

Repligen (NASDAQ:RGEN) last released its earnings results on Tuesday, May 5th. The biotechnology company reported $0.48 earnings per share for the quarter, beating the consensus estimate of $0.38 by $0.10. Repligen had a net margin of 6.73% and a return on equity of 4.88%. The business had revenue of $194.26 million during the quarter, compared to analysts’ expectations of $192.05 million. During the same quarter last year, the company earned $0.39 earnings per share. The firm’s revenue was up 14.8% on a year-over-year basis. Repligen has set its FY 2026 guidance at 1.970-2.050 EPS. On average, analysts forecast that Repligen will post 1.99 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Repligen

Several institutional investors and hedge funds have recently bought and sold shares of RGEN. Avidity Partners Management LP lifted its holdings in shares of Repligen by 54.7% in the 1st quarter. Avidity Partners Management LP now owns 77,800 shares of the biotechnology company’s stock valued at $9,166,000 after acquiring an additional 27,500 shares during the last quarter. Glenmede Trust Co. NA increased its position in shares of Repligen by 10.3% in the 1st quarter. Glenmede Trust Co. NA now owns 8,268 shares of the biotechnology company’s stock valued at $974,000 after purchasing an additional 770 shares during the last quarter. Summitry LLC increased its position in shares of Repligen by 37.0% in the 1st quarter. Summitry LLC now owns 2,385 shares of the biotechnology company’s stock valued at $281,000 after purchasing an additional 644 shares during the last quarter. Segall Bryant & Hamill LLC increased its position in shares of Repligen by 5.5% in the 1st quarter. Segall Bryant & Hamill LLC now owns 155,025 shares of the biotechnology company’s stock valued at $18,265,000 after purchasing an additional 8,045 shares during the last quarter. Finally, Amundi increased its position in shares of Repligen by 7.0% in the 1st quarter. Amundi now owns 44,959 shares of the biotechnology company’s stock valued at $5,297,000 after purchasing an additional 2,925 shares during the last quarter. 97.64% of the stock is owned by institutional investors.

About Repligen

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.